Ole Nordfang

1.8k total citations
50 papers, 1.4k citations indexed

About

Ole Nordfang is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Ole Nordfang has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 11 papers in Cardiology and Cardiovascular Medicine and 9 papers in Surgery. Recurrent topics in Ole Nordfang's work include Blood Coagulation and Thrombosis Mechanisms (33 papers), Hemophilia Treatment and Research (23 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Ole Nordfang is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (33 papers), Hemophilia Treatment and Research (23 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Ole Nordfang collaborates with scholars based in Denmark, United States and Sweden. Ole Nordfang's co-authors include Ulla Hedner, Mirella Ezban, Søren E. Bjørn, Lars C. Petersen, Thomas C. Beck, Per Østergaard, Kjeld Norris, Fanny Norris, Viggo Diness and LV Rao and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.

In The Last Decade

Ole Nordfang

50 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ole Nordfang Denmark 25 1.1k 354 208 200 179 50 1.4k
PW Majerus United States 13 848 0.8× 139 0.4× 333 1.6× 255 1.3× 96 0.5× 20 1.3k
Mohamed Hatmi France 18 330 0.3× 99 0.3× 168 0.8× 231 1.2× 132 0.7× 39 978
Jan Roodt South Africa 16 586 0.5× 131 0.4× 107 0.5× 169 0.8× 119 0.7× 30 980
Pauline F. Marx Netherlands 16 579 0.5× 84 0.2× 70 0.3× 166 0.8× 56 0.3× 27 891
N Yoshida Japan 15 358 0.3× 60 0.2× 103 0.5× 69 0.3× 53 0.3× 31 762
Qiufang Cheng United States 19 815 0.7× 958 2.7× 69 0.3× 127 0.6× 32 0.2× 34 1.3k
F Josso France 15 558 0.5× 178 0.5× 70 0.3× 47 0.2× 67 0.4× 73 845
Raffaella Guerriero Italy 16 494 0.4× 224 0.6× 26 0.1× 78 0.4× 86 0.5× 28 1.0k
Stephan Schwers Germany 16 273 0.2× 209 0.6× 253 1.2× 386 1.9× 71 0.4× 30 1.2k
Guangheng Zhu Canada 12 594 0.5× 63 0.2× 37 0.2× 118 0.6× 104 0.6× 21 893

Countries citing papers authored by Ole Nordfang

Since Specialization
Citations

This map shows the geographic impact of Ole Nordfang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Nordfang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Nordfang more than expected).

Fields of papers citing papers by Ole Nordfang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole Nordfang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Nordfang. The network helps show where Ole Nordfang may publish in the future.

Co-authorship network of co-authors of Ole Nordfang

This figure shows the co-authorship network connecting the top 25 collaborators of Ole Nordfang. A scholar is included among the top collaborators of Ole Nordfang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ole Nordfang. Ole Nordfang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bjørnsdottir, Inga, et al.. (2007). Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE. Journal of Pharmaceutical and Biomedical Analysis. 46(1). 82–87. 41 indexed citations
2.
3.
Nordfang, Ole, et al.. (2000). Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.. PubMed. 11(3). 239–42. 14 indexed citations
4.
Holst, Jan, Bengt Lindblad, David Bergqvist, et al.. (1997). The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.. Thrombosis Research. 86(4). 343–348. 14 indexed citations
5.
Holst, Jan, Bengt Lindblad, Ole Nordfang, Per Østergaard, & Ulla Hedner. (1996). Does Glycosylation Influence the Experimental Antithrombotic Effect of a Two-Domain Tissue Factor Pathway Inhibitor?. Pathophysiology of Haemostasis and Thrombosis. 26(1). 23–30. 2 indexed citations
6.
Ezban, Mirella, Michael Tvilling Madsen, Viggo Diness, et al.. (1995). Blocking of tissue factor pathway inhibitor (TFPl) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagulation & Fibrinolysis. 6(5). 388–394. 81 indexed citations
7.
8.
Lindahl, Anne Karin, et al.. (1994). Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagulation & Fibrinolysis. 5(5). 755–760. 16 indexed citations
9.
Brinkmann, Thomas, et al.. (1994). Synthesis of Tissue Factor Pathway Inhibitor in Human Synovial Cells and Chondrocytes Makes Joints the Predilected Site of Bleeding in Haemophiliacs. Clinical Chemistry and Laboratory Medicine (CCLM). 32(4). 313–318. 26 indexed citations
10.
Holst, Jan, Bengt Lindblad, David Bergqvist, et al.. (1994). Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.. PubMed. 71(2). 214–9. 36 indexed citations
11.
Østergaard, P., et al.. (1993). Is Tissue Factor Pathway Inhibitor Involved in the Antithrombotic Effect of Heparins?. Pathophysiology of Haemostasis and Thrombosis. 23(Suppl. 1). 107–111. 25 indexed citations
12.
13.
Holst, Jan, Bengt Lindblad, David Bergqvist, et al.. (1993). Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis. Thrombosis Research. 72(5). 467–470. 10 indexed citations
14.
Holst, Jan, Bengt Lindblad, David Bergqvist, et al.. (1993). Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in an Experimental Venous Thrombosis Model. Pathophysiology of Haemostasis and Thrombosis. 23(Suppl. 1). 112–117. 23 indexed citations
15.
Petersen, Lars C., Søren E. Bjørn, & Ole Nordfang. (1992). Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor. Thrombosis and Haemostasis. 67(5). 537–541. 71 indexed citations
16.
Lindahl, Anne Karin, Ulrich Abildgaard, Mette Lie Larsen, et al.. (1991). Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thrombosis Research. 62(6). 607–614. 24 indexed citations
17.
Lindahl, Anne Karin, et al.. (1991). Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thrombosis Research. 61. 39–48. 27 indexed citations
18.
Nordfang, Ole & Mirella Ezban. (1988). Generation of active coagulation factor VIII from isolated subunits.. Journal of Biological Chemistry. 263(3). 1115–1118. 39 indexed citations
19.
Nordfang, Ole, Mirella Ezban, Jennifer M. Favaloro, Helena Dahl, & Jan J. Hansen. (1985). Specificity of Monoclonal Antibodies to Factor VIII: C. Thrombosis and Haemostasis. 54(3). 586–590. 8 indexed citations
20.
Nordfang, Ole. (1981). A RADIOIMMUNOASSAY FOR THE DETECTION OF IDIOTYPES IN ALLOANTIGEN REACTIVE MOUSE SERA AND IN NORMAL MOUSE SERA. Acta Pathologica Microbiologica Scandinavica Section C Immunology. 89C(1-6). 43–48. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by PW Majerus Breakdown of academic impact, for papers by Mohamed Hatmi Breakdown of academic impact, for papers by Jan Roodt Breakdown of academic impact, for papers by Pauline F. Marx Breakdown of academic impact, for papers by N Yoshida Breakdown of academic impact, for papers by Qiufang Cheng Breakdown of academic impact, for papers by F Josso Breakdown of academic impact, for papers by Raffaella Guerriero Breakdown of academic impact, for papers by Stephan Schwers Breakdown of academic impact, for papers by Guangheng Zhu
Rankless by CCL
2026